PF-08656796 / Pfizer - LARVOL DELTA

Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion acquisition of Metsera. (FierceBiotech) - "The oral, fully biased, ultra-long-acting GLP-1 drug, dubbed MET-224o, was one of the rewards from Pfizer's successful resolution of the bidding war with Novo Nordisk last year to secure Metsera....The other, called MET-097o, was an oral formulation...The other clinical-stage obesity prospect to be scrapped by Pfizer this morning is PF-07976016...They included PF-07258669, an MC4R antagonist for malnutrition that had already seen its phase 1 study cut short earlier this year for business reasons....The last of Pfizer's abandoned assets was PF-07985631, which was in phase 1 development for nephropathy."

Discontinued • Cachexia • Obesity • Renal Disease

Pipeline Highlights and Upcoming Milestones (Metsera Press Release) - "We expect to release topline data from VESPER-1 together with interim data from the titration phase of VESPER-3 in September 2025. Combined, these data will inform the weekly dosing regimens we plan to investigate in Phase 3 trials; We expect to release topline 28-week results from the monthly dosing portion of VESPER-3 by year-end 2025 or in early 2026; We are on track to initiate the Phase 3 program of MET-097i in late 2025...We expect to announce topline 12-week data from the MET-233i monotherapy trial in late 2025...We expect to announce topline 12-week data from the MET-233/097 co-administration trial by year-end 2025 or in early 2026....MET-097o program and alternate candidate MET-224o on track; four-week topline data for selected lead expected in late 2025."

Clinical data • Preclinical • Obesity

Oral peptide platform: MET-097o oral program accelerated and alternate oral candidate MET-224o on track; four-week data for selected lead expected in late 2025 (GlobeNewswire) - "We plan to initiate Phase 1 trials of MET-097o and MET-224o in mid-2025, and to select and advance the best-performing oral candidate based on the Phase 1 clinical data. Preliminary four-week weight loss, tolerability, and pharmacokinetic data for the selected lead candidate are expected in late 2025."

P1 data • Preclinical • Obesity